BayMed Venture Partners

BayMed invests across early-stage, expansion, and growth-stage companies. The firm's stage flexibility reflects the capital-intensive nature of life sciences, where companies often need funding through clinical trials, regulatory approvals, and early commercialization before reaching revenue scale. This multi-stage approach allows BayMed to support portfolio companies from pre-revenue R&D through market expansion.

The firm targets the convergence of technology and life sciences, with a mandate spanning medical devices, digital health, and healthcare services. BayMed's thesis centers on innovations that navigate the intersection of clinical science and commercial scalability — companies that require both technical validation and regulatory clearance to reach the market.

Public records do not confirm the firm's specific fund structure, total assets under management, or number of vehicles. BayMed's website provides limited disclosure on fundraising history. Institutional allocators should request fund-level track records and vehicle documentation directly from the firm.

The firm's sourcing network is not publicly detailed. Given BayMed's San Francisco base, proximity to academic medical centers and the Bay Area biotech ecosystem likely informs deal flow, though no specific partnerships, incubator relationships, or proprietary sourcing channels are confirmed in available public disclosures.

Registration status is not confirmed through the firm's limited public disclosures. Institutional counterparties conducting due diligence should verify BayMed's regulatory filings and Form ADV through the SEC's Investment Adviser Public Disclosure database to determine registration status, disciplinary history, and reported assets.